DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

AZN·AstraZeneca

$.
-. (-.%)
Pre-Market
High
$170.32
Open
$168.35
Market Cap
196.50B
52W High
$15,730.00
Low
$167.98
P. Close
$172.07
P/E
25.19
52W Low
$10,700.00
Fwd P/E
19.41
DailyIQ Est.
$219.40
Technical Score (1D)
27
SELL
News Sentiment
62
BULLISH
Morningstar’s latest analyst report on AstraZeneca, released 8.8 hours ago, revises the company’s valuation and target price after evaluating its pipeline, recent earnings, and competitive positioning. The report highlights that the firm’s oncology and rare disease portfolios have delivered stronger revenue growth in Q2 2026, a trend that underpins the upward revision of the target price. However, the same report flags regulatory and competitive risks that could temper the upside, suggesting that the market should remain cautious over the next ten trading days. Earlier this week, AstraZeneca’s earnings call confirmed robust growth in oncology and a pipeline expansion in rare diseases, reinforcing the narrative that the company is capitalizing on new indications. Despite this positive momentum, a separate analyst note 15 hours ago warned that a rare disease therapy has encountered a regulatory or clinical setback, which could erode the projected revenue gains from that segment. The setback introduces uncertainty into the rare disease pipeline, potentially affecting investor sentiment and the company’s earnings outlook for the remainder of the year. Consequently, traders should monitor the regulatory status updates for the affected rare disease drug, as any clearance or further delay will materially influence the stock’s near‑term trajectory. Additionally, watch for Omeros’ earnings releases, as the analyst believes the setback could create a competitive opportunity for the rival, which may shift market dynamics in the rare disease space. Finally, keep an eye on macroeconomic data releases that could impact the broader pharmaceutical sector, as the analyst report notes sensitivity to macro factors such as interest rates and healthcare spending. These developments collectively suggest that while the company’s core oncology growth remains solid, the rare disease setback and macro risks will be key drivers of price action over the next trading week.
Earnings Summary
AstraZeneca PLC is a global biopharmaceutical company engaged in the research, development, production, and commercialization of prescription medicines across key therapeutic areas including oncology, cardiovascular, renal and metabolism, and respiratory & immunology. Operating within the Healthcare sector, specifically the Drug Manufacturers - General industry, AstraZeneca focuses on delivering innovative treatments to patients worldwide through strategic partnerships and direct engagement with healthcare professionals. The company's recent quarterly performance shows a mixed pattern of exceeding or meeting analyst expectations for Earnings Per Share (EPS). In Q3 2025, AZN reported EPS of $1.19, surpassing the estimate of $1.13, with revenue at $15.19 billion. This followed Q2 2025, where EPS was $1.085 against an estimate of $1.46, and revenue was $14.46 billion. Prior to this, Q1 2025 saw EPS of $1.245, beating the estimate of $1.12, with revenue at $13.59 billion, and Q4 2024 reported EPS of $1.045, slightly above the estimate of $1.04, with revenue at $14.89 billion. Revenue has shown a general upward trend across the reported quarters, with Q1 2025 revenue at $13.59 billion, Q2 2025 at $14.46 billion, Q3 2025 at $15.19 billion, and projected Q1 2026 revenue at $15.36 billion, and Q2 2026 at $15.94 billion. Historically, AstraZeneca has demonstrated consistent revenue growth, with recent quarters generally showing year-over-year increases, driven by its key drug portfolios. The company has a track record of meeting or beating analyst EPS estimates in most of the recent quarters, with a notable beat in Q1 2025 and Q3 2025, and a slight beat in Q4 2024, though Q2 2025 saw a miss. Recent news highlights positive developments for Enhertu, with a recommendation for approval in the EU for unresectable or metastatic HER2-positive solid tumors, and expanded indications for Datopotamab deruxtecan in breast cancer, underscoring progress in its oncology pipeline. The company also reported strong Q1 revenue growth driven by its Oncology and Rare Disease segments and reaffirmed its 2026 guidance. Investors will be watching for the formal EU approval of Enhertu and the market uptake of Datroway, as well as continued performance updates from the Oncology and Rare Disease portfolios, and the company's ability to meet its mid-to-high single-digit revenue and low double-digit EPS growth targets for 2026.

EPS

EstBeatMiss
$0.97$1.11$1.25$1.39$1.53Q4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$1.22 - -
Q3'25$1.13$1.19+4.9%
Q2'25$1.46$1.08-25.9%
Q1'25$1.12$1.25+11.6%
Q4'24$1.04$1.04+0.8%

Revenue

EstBeatMiss
$13.3B$13.9B$14.5B$15.1B$15.6BQ4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$15.4B - -
Q3'25 - $15.2B -
Q2'25 - $14.5B -
Q1'25 - $13.6B -
Q4'24 - $14.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AZN Stock Snapshot

AZN is currently trading at $170.09, giving AstraZeneca a market cap of 196.50B and a P/E ratio of 25.2. Today's range spans $167.98–$170.32, with shares opening at $168.35 and moving down $1.98 (1.2%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 62/100.

Over the past year AZN has traded between $10700.00 and $15730.00 - the current price is -98.4% off the 52-week low and -98.9% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $213.99 (range $184.00–$240.00), implying upside of +25.8%.

Short sellers have a clear thesis in AZN - large-cap, Healthcare, 196.50B market cap. Score: 27/100 (SELL). Sentiment: bullish (62/100). Price: $170.09 (near 52-week lows). The current P/E ratio stands at 25.2. At this capitalization tier, the borrow is relatively easy, the liquidity absorbs the size, and the technical confirmation provides a clean stop-out level. The 52-week range of $10700.00–$15730.00 establishes the structural target zones - and the SELL signal is the systematic entry trigger.

When a large-cap Healthcare name with 196.50B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (62/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $170.09 (near 52-week lows in the $10700.00–$15730.00 range), the structural support levels are where that sponsorship question gets answered.